BackIntra-Cellular Therapies Overview

Intra-Cellular Therapies Accounts Payable

Intra-Cellular Therapies's accounts payable is $26M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$26.07M
↑ 127.68% YoYΔ $14.62M vs prior year quarter

Peer trimmed avg / median

Loading

Intra-Cellular Therapies Accounts Payable History

Loading

Intra-Cellular Therapies vs. peers: Accounts Payable Comparison

Loading

Intra-Cellular Therapies Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Intra-Cellular Therapies (ITCI) FAQ

As of the most recent data (December 2024), ITCI shows a accounts payable of $26M. That compares with $11M in the prior-year period — up 127.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's accounts payable is now $26M (was $11M) — a 127.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

Tracking ITCI's accounts payable over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $26M That compares with $11M in the prior-year period — up 127.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $26M) with ownership activity and broader fundamentals.

Intra-Cellular Therapies's accounts payable is $26M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.